Avadel Pharmaceuticals
Stock Forecast, Prediction & Price Target
Avadel Pharmaceuticals (AVDL) stock Price Target by analysts
$30
Potential upside: 118.18%
Avadel Pharmaceuticals price prediction
What is Avadel Pharmaceuticals stock analysts` prediction?
Avadel Pharmaceuticals stock forecast: Based on 1 Wall Street analysts` predicted price targets for Avadel Pharmaceuticals in the last 3 months, the avarage price target is $30, with a high forecast of $NaN. The average price target represents a 118.18% change from the last price of $13.75.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Avadel Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Avadel Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Francois Brisebois Oppenheimer | 0% 0/1 | 11 months ago | $30 118.18% upside | $12.91 | StreetInsider | Previous targets (0) |
Oren Livnat H.C. Wainwright | 0% 0/1 | over 1 year ago | $27 96.36% upside | $16.25 | StreetInsider | Previous targets (0) |
Unknown Jefferies | N/A | almost 3 years ago | $11 -20% downside | $8.85 | Benzinga | N/A |
Unknown Leerink Partners | N/A | about 3 years ago | $12 -12.72% downside | $7.14 | Benzinga | N/A |
Unknown Needham | N/A | about 3 years ago | $9 -34.54% downside | $7.31 | Benzinga | N/A |
Chris Howerton Jefferies | 100% 1/1 | about 3 years ago | $8 -41.81% downside | $7.31 | TheFly | Previous targets (0) |
Unknown Needham | N/A | over 3 years ago | $6 -56.36% downside | $2.5 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 3 years ago | $6 -56.36% downside | $1.07 | Benzinga | N/A |
Unknown H.C. Wainwright | N/A | over 3 years ago | $13 -5.45% downside | $2.36 | Benzinga | N/A |
Avadel Pharmaceuticals Financial Estimates
Avadel Pharmaceuticals Revenue Estimates
Avadel Pharmaceuticals EBITDA Estimates
Avadel Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $27.96M 0% | Avg: $298.29M Low: $253.26M High: $340.78M avg. 966.76% | Avg: $400.20M Low: $345.67M High: $448.12M avg. 34.16% | Avg: $478.26M Low: $413.10M High: $535.53M avg. 19.50% | Avg: $542.57M Low: $468.64M High: $607.54M avg. 13.44% |
Net Income
% change YoY
| $-77.32M N/A | $-137.46M -77.76% | $-160.27M -16.59% | Avg: $58.64M Low: $-2.40M High: $88.19M avg. 136.59% | Avg: $166.47M Low: $102.62M High: $176.38M avg. 183.86% | Avg: $172.85M Low: $142.23M High: $199.76M avg. 3.82% | Avg: $220.47M Low: $181.42M High: $254.79M avg. 27.55% |
EBITDA
% change YoY
| $-84.56M N/A | $-93.72M -10.82% | $-149.12M -59.11% | Avg: $-14.44M Low: $-16.50M High: $-12.26M avg. 90.31% | Avg: $-19.38M Low: $-21.70M High: $-16.74M avg. -34.16% | Avg: $-23.16M Low: $-25.93M High: $-20.00M avg. -19.50% | Avg: $-26.27M Low: $-29.42M High: $-22.69M avg. -13.44% |
EPS
% change YoY
| -$1.32 N/A | -$2.29 -73.48% | -$2 12.66% | Avg: $0.59 Low: -$0.03 High: $1.1 avg. 129.56% | Avg: $1.67 Low: $1.28 High: $2.2 avg. 182.02% | Avg: $2.16 Low: $1.77 High: $2.49 avg. 29.29% | Avg: $2.75 Low: $2.26 High: $3.18 avg. 27.55% |
Operating Expenses
% change YoY
| $85.59M N/A | $95.21M 11.23% | $164.96M 73.25% | Avg: $556.19M Low: $472.21M High: $635.40M avg. 237.15% | Avg: $746.19M Low: $644.52M High: $835.54M avg. 34.16% | Avg: $891.75M Low: $770.25M High: $998.53M avg. 19.50% | Avg: $1.01B Low: $873.81M High: $1.13B avg. 13.44% |
FAQ
What is Avadel Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 87.95% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -2.40M, average is 58.64M and high is 88.19M.
What is Avadel Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 258.46% in 2025-2028.
We have gathered data from 7 analysts. Their low revenue estimate is $253.26M, average is $298.29M and high is $340.78M.
What is Avadel Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 92.10% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$0.03, average is $0.59 and high is $1.1.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Avadel Pharmaceuticals stock. The most successful analyst is Francois Brisebois.